Weekly Research Analysts’ Ratings Changes for Exelixis (EXEL)

Exelixis (NASDAQ: EXEL) recently received a number of ratings updates from brokerages and research firms:

• 3/2/2026 – Exelixis had its price target lowered by Royal Bank Of Canada from $46.00 to $43.00. They now have a “sector perform” rating on the stock.
• 3/2/2026 – Exelixis was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 2/22/2026 – Exelixis was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 2/14/2026 – Exelixis was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 2/12/2026 – Exelixis had its price target raised by HC Wainwright from $52.00 to $54.00. They now have a “buy” rating on the stock.
• 2/11/2026 – Exelixis had its price target raised by Stifel Nicolaus from $43.00 to $44.00. They now have a “hold” rating on the stock.
• 2/11/2026 – Exelixis had its price target raised by Royal Bank Of Canada from $45.00 to $46.00. They now have a “sector perform” rating on the stock.
• 2/11/2026 – Exelixis had its price target raised by Wells Fargo & Company from $30.00 to $35.00. They now have an “equal weight” rating on the stock.
• 2/4/2026 – Exelixis had its price target raised by Barclays PLC from $41.00 to $44.00. They now have an “equal weight” rating on the stock.
• 2/4/2026 – Exelixis was upgraded by Zacks Research from “hold” to “strong-buy”.
• 2/3/2026 – Exelixis had its “buy” rating reaffirmed by HC Wainwright. They now have a $52.00 price target on the stock.
• 2/2/2026 – Exelixis had its price target raised by Morgan Stanley from $48.00 to $49.00. They now have an “equal weight” rating on the stock.
• 1/27/2026 – Exelixis had its price target raised by HC Wainwright from $49.00 to $52.00. They now have a “buy” rating on the stock.
• 1/22/2026 – Exelixis had its “buy (b)” rating reaffirmed by Weiss Ratings.
• 1/14/2026 – Exelixis was given a new $51.00 price target by Truist Financial Corporation.
• 1/8/2026 – Exelixis had its price target raised by HC Wainwright from $49.00 to $52.00. They now have a “buy” rating on the stock.
• 1/8/2026 – Exelixis had its “equal weight” rating reaffirmed by Morgan Stanley. They now have a $48.00 price target on the stock, up from $45.00.
• 1/5/2026 – Exelixis was downgraded by Citigroup Inc. from “market outperform” to “underperform”.
• 1/5/2026 – Exelixis was given a new $41.00 price target by UBS Group AG.
• 1/5/2026 – Exelixis was downgraded by Bank of America Corporation from “neutral” to “underperform”. They now have a $41.00 price target on the stock.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Dana Aftab sold 47,918 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $44.50, for a total transaction of $2,132,351.00. Following the sale, the executive vice president directly owned 616,106 shares of the company’s stock, valued at $27,416,717. This trade represents a 7.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick J. Haley sold 67,814 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $43.52, for a total transaction of $2,951,265.28. Following the transaction, the executive vice president owned 381,908 shares of the company’s stock, valued at approximately $16,620,636.16. This represents a 15.08% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 362,849 shares of company stock valued at $15,917,463 in the last quarter. Insiders own 2.85% of the company’s stock.

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.